This article is for educational and general wellness purposes only. It is not medical advice and is not intended to diagnose, treat, cure, or prevent any disease. If you are noticing changes in your body or have questions about your health, please consult a knowledgeable healthcare provider.

And when your vagina starts itching, burning, or feeling like sandpaper, it can be confusing to figure out what's actually going on.

So let's break it down: what is vaginal atrophy? How does it differ from GSM? And why does it feel so different for every woman?

How is Atrophy Defined?

Vaginal atrophy is the thinning, drying, and loss of elasticity in the vaginal and vulvar tissues associated with decreased estrogen levels, most commonly in perimenopause and post-menopause. Estrogen is involved in maintaining vaginal blood flow, tissue integrity, and moisture. When levels decline, so does vaginal comfort (Sturdee & Panay, 2010).

The word "atrophy" stems from Greek roots meaning "without nourishment." Not exactly the empowering vibe we're going for — but unfortunately, that's exactly what happens when estrogen leaves the party.

Without it, vaginal tissues:

• Thin and become more delicate
• Lose their ability to stretch
• Produce less lubrication
• Become more prone to irritation and sensitivity

Yet, the lived experience of this can be wildly different depending on the woman — and even the day.

Ok, What About GSM?

Genitourinary Syndrome of Menopause (GSM) was introduced in 2014 to better describe the range of changes caused by the decline in estrogen and androgens during menopause (Portman & Gass, 2014). The term replaced "vaginal atrophy" because:

• It includes urinary changes like urgency and recurrent discomfort
• It reflects sexual changes like shifts in libido and discomfort during sex
• It moves away from pathologizing or shaming language

Why the update matters: around 50–70% of postmenopausal women experience GSM-related changes, yet fewer than 25% seek help (Kingsberg et al., 2013). Why? Because shame, stigma, and poor communication mean many women suffer in silence.

Let's Talk Vaginal Discomfort...

Not all vaginal discomfort is the same. In fact, many women experience:

• Itching & burning: Common early changes, often confused with yeast infections. These experiences may stem from inflammation, pH shifts, and changes to the epithelium as estrogen fluctuates.
• Sensitivity or discomfort during sex: Some women notice increased sensitivity or discomfort during sex as vaginal tissue changes. Even normal movement can cause irritation in more advanced cases.
• Stabbing or sharp sensations: May indicate changes to nerve endings or pelvic floor tension. Ongoing discomfort like this can affect body image and sexual confidence.
• Soreness or rawness: A constant, dull ache tied to tissue changes and pelvic tension as estrogen shifts.

Psychologically, these changes often lead to anticipatory anxiety. Women begin to fear sex or routine activities like riding a bike or wearing certain underwear. Research shows that sexual discomfort is closely associated with lower self-esteem, anxiety, and avoidance behavior — which can negatively affect relationships and mental health (Nappi et al., 2003).

If you want to dig deeper into the different types of vaginal discomfort and what may be contributing to each, a knowledgeable healthcare provider or menopause specialist is your best resource.

Sex, Drugs, & Rock and Roll

(By that we mean: Hormones)

Let's get honest. When discomfort or dryness shows up, libido doesn't just leave — it sprints out the door.

Here's why:

• Discomfort leads to avoidance — The brain quickly links sexual activity with discomfort. Ongoing discomfort can create a cycle where intimacy feels less appealing, especially if the root cause isn't addressed.
• Medications don't help — SSRIs, antihistamines, and antihypertensives can worsen dryness or suppress libido. One study estimates that up to 50% of women on SSRIs report some degree of sexual changes (Serretti & Chiesa, 2009).
• There's a huge treatment gap — Testosterone replacement is FDA-approved for men, but no equivalent libido-supporting hormone is routinely approved or prescribed for women. Gee, we wonder what's going to happen with that disparity? 🙄
• Sexual scripts change — Women often report a drop in spontaneous desire but maintain responsive desire — meaning desire arises in safe, supported, and comfortable settings (Basson, 2000).
• Relationships feel the impact — Many postmenopausal women share that these changes affect their intimacy and relational connection. It's a real, widely experienced part of this stage of life.

This isn't just a vaginal issue — it's a whole-self issue.

What the Research Says About Estriol

Estriol is a naturally occurring form of estrogen. When applied topically, it works locally — meaning it stays where it's applied rather than circulating systemically the way oral hormones do. For that reason, it's been studied specifically in the context of vaginal comfort during and after menopause.

What research suggests:

• Tissue comfort and appearance: Estriol is associated with improved tissue comfort, a visibly more supple appearance, and better hydration (Leibbrand et al., 1992).
• Moisture and softness: Estrogen is involved in how mucous membranes stay hydrated and flexible — in plain terms, it's part of what keeps things comfortable down south.
• A balanced intimate environment: Estrogen's role in vaginal biology is associated with supporting a balanced intimate environment and everyday freshness.
• Comfort and satisfaction: Research suggests estriol may be associated with improved comfort and satisfaction for many women (Krychman et al., 2017).

If you're curious whether topical estriol might be right for you, that's a great conversation to have with your healthcare provider — especially if you've noticed changes in vaginal comfort, moisture, or tissue sensitivity.

---

References:
Basson, R. (2000). The female sexual response: A different model. Journal of Sex & Marital Therapy, 26(1), 51–65.
Kingsberg, S. A., Wysocki, S., Magnus, L., & Krychman, M. (2013). Vulvar and vaginal atrophy in postmenopausal women: Findings from the REVIVE survey. Journal of Sexual Medicine, 10(7), 1790–1799.
Krychman, M., Graham, S., Bernick, B., Mirkin, S., & Portman, D. (2017). The Women's EMPOWER survey: Sexual health during the menopausal transition and beyond. Journal of Sexual Medicine, 14(6), 733–741.
Leibbrand, H., Schmidt-Gollwitzer, M., Gollwitzer, U., & Neiss, A. (1992). Clinical effectiveness of estriol in treating vaginal atrophy. Maturitas, 15(Suppl), 59–70.
Nappi, R. E., Palacios, S., Panay, N., & Particco, M. (2003). Psychological symptoms and their correlation with sexual function in postmenopausal women. Climacteric, 6(5), 394–403.
Portman, D. J., & Gass, M. L. (2014). Genitourinary syndrome of menopause: New terminology for vulvovaginal atrophy. Menopause, 21(10), 1063–1068.
Serretti, A., & Chiesa, A. (2009). Treatment-emergent sexual dysfunction related to antidepressants: A meta-analysis. Journal of Clinical Psychopharmacology, 29(3), 259–266.
Sturdee, D. W., & Panay, N. (2010). Recommendations for the management of postmenopausal vaginal atrophy. Climacteric, 13(6), 509–522.